Balance Sheet
Liabilities and Shareholders Equity
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Liabilities and Shareholders Equity (2017 - 2024)

KalVista Pharmaceuticals' Liabilities and Shareholders Equity history spans 10 years, with the latest figure at $294.8 million for Q4 2024.

  • For Q4 2024, Liabilities and Shareholders Equity changed N/A year-over-year to $294.8 million; the TTM value through Apr 2025 reached $655.8 million, up 1.14%, while the annual FY2024 figure was $235.4 million, N/A changed from the prior year.
  • Liabilities and Shareholders Equity for Q4 2024 was $294.8 million at KalVista Pharmaceuticals, up from $160.8 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $294.8 million in Q4 2024 and bottomed at $66.2 million in Q1 2021.
  • The 4-year median for Liabilities and Shareholders Equity is $126.4 million (2023), against an average of $143.8 million.
  • The largest annual shift saw Liabilities and Shareholders Equity plummeted 35.68% in 2021 before it grew 24.86% in 2024.
  • A 4-year view of Liabilities and Shareholders Equity shows it stood at $75.4 million in 2020, then decreased by 12.25% to $66.2 million in 2021, then skyrocketed by 109.56% to $138.7 million in 2023, then soared by 112.49% to $294.8 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Liabilities and Shareholders Equity are $294.8 million (Q4 2024), $160.8 million (Q4 2024), and $200.2 million (Q3 2024).